Last week’s full-year results from GlaxoSmithKline (GSK) do not answer every concern the sceptics may have regarding current ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Record FY2024 development sales of AED 33.6 billion, up 20% YoY driven by strong demand for new launches and existing ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...

This is the conclusion of a recent analysis by commercial real estate investment firm Berkadia, which predicts Orlando will ...

Corporation, a biopharmaceutical company specializing in the discovery, development, and commercialization of proprietary ...

Refine unveils its state-of-the-art new HQ and Sales Gallery in the sky on 47th floor of Ubora Tower in Business Bay spanning ...

Refine's new HQ offers panoramic views of Downtown Dubai & Burj Khalifa.. Refine unveils $12 bn development portfolio for ...

Meanwhile, vaccine sales slipped by 4% for the year ... and GSK has to prove its drug development pipeline is packed with new blockbuster treatments. “An increased dividend and the launch ...

roughly matching last quarter’s sales. This year could have significant news flow for Sanofi’s pipeline. On Feb. 22, Sanofi’s partner Teva will present more detailed information on its ...